Wall Street brokerages predict that Ultragenyx Pharmaceutical (NASDAQ:RARE) will post earnings per share of ($0.76) for the current fiscal quarter, according to Zacks. Nine analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings, with the lowest EPS estimate coming in at ($2.20) and the highest estimate coming in at $0.91. Ultragenyx Pharmaceutical reported earnings of ($1.63) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 53.4%. The business is expected to announce its next quarterly earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full year earnings of ($6.14) per share for the current fiscal year, with EPS estimates ranging from ($8.73) to ($2.54). For the next financial year, analysts expect that the business will report earnings of ($6.69) per share, with EPS estimates ranging from ($8.74) to ($5.20). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($2.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.00) by ($0.27). The business had revenue of $2.41 million during the quarter, compared to the consensus estimate of $0.75 million. During the same quarter in the prior year, the company earned ($1.75) EPS.
A number of equities analysts have issued reports on the company. Bank of America increased their price target on Ultragenyx Pharmaceutical from $61.00 to $72.00 in a research report on Tuesday. BidaskClub upgraded Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday. ValuEngine raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, April 11th. Piper Jaffray reissued an “overweight” rating and set a $67.00 target price on shares of Ultragenyx Pharmaceutical in a report on Thursday, March 22nd. Finally, Robert W. Baird reissued a “buy” rating and set a $70.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, February 23rd. One analyst has rated the stock with a sell rating, six have issued a hold rating and fifteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $69.41.
Several large investors have recently bought and sold shares of RARE. First Trust Advisors LP increased its holdings in shares of Ultragenyx Pharmaceutical by 49.4% in the fourth quarter. First Trust Advisors LP now owns 785,694 shares of the biopharmaceutical company’s stock valued at $36,440,000 after purchasing an additional 259,816 shares during the last quarter. Pier Capital LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $5,831,000. Hudson Bay Capital Management LP acquired a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $4,638,000. Opaleye Management Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $4,174,000. Finally, Alliancebernstein L.P. increased its holdings in shares of Ultragenyx Pharmaceutical by 8.7% in the fourth quarter. Alliancebernstein L.P. now owns 700,406 shares of the biopharmaceutical company’s stock valued at $32,485,000 after purchasing an additional 56,106 shares during the last quarter. 87.19% of the stock is owned by hedge funds and other institutional investors.
RARE stock traded up $0.97 during mid-day trading on Thursday, reaching $54.79. 829,243 shares of the company’s stock were exchanged, compared to its average volume of 553,407. The company has a market capitalization of $2,635.06, a P/E ratio of -7.31 and a beta of 1.82. Ultragenyx Pharmaceutical has a 12-month low of $41.67 and a 12-month high of $71.99.
TRADEMARK VIOLATION WARNING: “-$0.76 Earnings Per Share Expected for Ultragenyx Pharmaceutical (RARE) This Quarter” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/17/0-76-earnings-per-share-expected-for-ultragenyx-pharmaceutical-rare-this-quarter.html.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.